Thought Leader Liaison Dermatology
About the job
- A bachelor's degree is required.
- At least 5 years of experience in pharma or biotech is required.
- Proven experience in KOL engagement, thought leader marketing, or field-based strategy roles such as TLL, MSL, or Marketing is required.
- A valid driver's license is required.
- Must reside within the assigned territory.
- Willingness to travel 60–70% is required.
- Orchestrate resources with the top 10–15% of assigned KOLs in alignment with cross-functional account plans.
- Identify, profile, cultivate, and maintain long-term relationships with KOLs within the dermatology community.
- Conduct substantial on-label business conversations focused on product, disease state, and company topics at appropriate venues.
- Execute unique, on-label, and approved KOL programming, including disease state education for fellowship programs.
- Serve as a single point of contact to resolve KOL issues when directed by the DTLL and/or Headquarters.
- Assist with compliant KOL development, including speakers, using approved decks and materials.
- Plan and execute KOL engagements and executive encounters at local, regional, and national conferences, POAs, field engagements, and other venues in a compliant manner.
- Orchestrate KOL executive encounters and engagements across all relevant settings.
- Collaborate with targeted KOLs to obtain feedback on dermatology franchise and brand-related marketing strategies or materials, all of which are pre-approved by legal, compliance, and regulatory.
- Provide feedback to commercial leadership on various topics as requested.
- Serve as a single point of contact for high-volume speaker logistics and scheduling.
- Provide advisory board participant and speaker recommendations to Marketing.
- Assist in execution of commercial contracts when requested.
- Execute and lead specific TLL initiatives to support brand strategy.
- Work closely with ZBDs, RBDs, ABMs, and home office colleagues in Marketing, Medical Affairs, Sales, and Market Access.
- Collaborate with TLLs from the Alliance.
- Lead TLL projects and initiatives.
- An advanced degree (MBA, PharmD, or PhD) is preferred.
- Significant exposure to dermatology or immunology is preferred.
- A strong understanding of the dermatology landscape, including atopic dermatitis and biologic therapies, is preferred.
- Dermatology or biologic marketplace experience is preferred.
- Cross-functional leadership capability is preferred.
- A deep understanding of compliance and regulatory boundaries is preferred.
About the company
Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Get referred to Sanofi
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
- June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
- Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.
What critics are saying
- Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
- Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
- Dupixent concentration makes 2030s patent loss an existential revenue shock.
What makes Sanofi unique
- Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
- October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
- Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Health Insurance
- Professional Development Budget
- Parental Leave